Israel’s Teva has received US FDA approval for its Truxima treatment for several conditions of the deadly non-Hodgkin’s lymphoma, a type of blood cancer. Truxima is a bio-similar (tested low-cost alternative) to Rituxan (Rituximab) manufactured by Roche.

https://www.calcalistech.com/ctech/articles/0,7340,L-3750979,00.html

https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm627035.htm